^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/02/2021
    Excerpt:
    RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of...Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) (1.1)...Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
    Secondary therapy:
    Chemotherapy; CHOP
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

    Excerpt:
    ...- Pathologically confirmed CD20 positive diffuse large B-cell lymphoma (DLBCL) after surgical resection...
    Trial ID:
    NCT01279902
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...- Histologically confirmed CD20-positive, diffuse large B-cell lymphoma...
    Trial ID:
    NCT00831597
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

    Excerpt:
    ...Patients with histologically proven diffuse large B-cell (CD20 positive) or transformed follicular non-Hodgkin's lymphomas, that have relapsed after conventional chemotherapy and are...
    Trial ID:
    NCT00472056
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)

    Excerpt:
    ...Histology verified according to the WHO classification and with CD20 positivity by immunhistochemistry or flow cytometry:...
    Trial ID:
    NCT01502982
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

    Excerpt:
    ...- Histologically proven CD20 positive diffuse large B-cell non-Hodgkin's lymphoma...
    Trial ID:
    NCT01990144
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...- Histologically confirmed, CD20 positive, diffuse large B-cell lymphoma (DLCL)...
    Trial ID:
    NCT00575406
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...- Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells...
    Trial ID:
    NCT01118845
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

    Excerpt:
    ...- Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder...
    Trial ID:
    NCT00010192
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

    Excerpt:
    ...- Histologically confirmed diagnosis of CD20 positive, diffuse large B-cell NHL; de novo or transformed histologies are acceptable...
    Trial ID:
    NCT00504751
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

    Excerpt:
    ...Diagnosis of diffuse large B-cell lymphoma, CD20-positive, according to the World Health Organization Classification, stages II-IV or limited stage I disease that is bulky (more than 10 cm) or with International Prognostic Index (IPI) score > 1....
    Trial ID:
    NCT00450385
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

    Excerpt:
    ...Lenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) following at least one prior standard systemic treatment regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least one prior line of salvage therapy with...
    Trial ID:
    NCT02031419
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

    Excerpt:
    ...- Histological confirmation of relapsed/refractory CD20 positive diffuse large B-cell lymphoma...
    Trial ID:
    NCT01959698
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

    Excerpt:
    ...- histologically confirmed DLBCL, CD20 positive....
    Trial ID:
    DR-CHOP
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A multicenter, double-arm, randomized, prospective II phase controlled clinical trial to evaluate the efficacy and safety of dexitabine combined with R-GDP compared with R-CHOP in patients with mid-term PET-CT positive newly diagnosed diffuse large B-cell lymphoma ((DLBCL)).

    Excerpt:
    ...In patients with diffuse large B-cell lymphoma confirmed by pathology, CD20 was positive; 3. ...
    Trial ID:
    ChiCTR2000035106
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Multicenter, randomized, double-blind, and parallel active controlled trial for comparing the efficacy and safety of Haizheng recombinant human - mouse chimeric anti-CD20 monoclonal antibody injection (HS006) combined with CHOP(Hi-chop) and Rituximab combined with CHOP(R-chop) in initial treatment for patients with diffuse large B

    Excerpt:
    ...Histopathologically diagnosed with CD20 positive diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS). ...
    Trial ID:
    ChiCTR2000040602
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study

    Excerpt:
    ...Relapsed or progressive Cluster Designation 20 (CD20) positive diffuse large B-cell lymphoma including induction failures to first-line anthracycline-containing regimens and not usually considered eligible for high dose chemotherapy and stem cell transplantation. ...
    Trial ID:
    ACTRN12606000373572
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical study of obrutinib, lenalidomide combined with rituximab in the treatment of relapsed/refractory diffuse large B-cell lymphoma in elderly patients based on comprehensive geriatric assessment system

    Excerpt:
    ...Cd20-positive diffuse large B-cell lymphoma independently diagnosed by two pathologists; 2. ...
    Trial ID:
    ChiCTR2200066211
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    'A multi-centre phase II trial of early treatment intensification with R-ICE (rituximab – ifosfamide, carboplatin, etoposide) chemotherapy followed by BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) high dose chemotherapy and autologous stem cell transplantation for patients with poor prognosis diffuse large B-cell lymphoma

    Excerpt:
    ...Diagnosis of CD20-positive diffuse large B-cell lymphoma on biopsy...
    Trial ID:
    ACTRN12609001077257
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A multicenter, randomized, single blind, multi dose, positive drug parallel controlled phase II clinical trial to evaluate the efficacy and safety of Hisun recombinant chimeric human-mouse anti-CD20 monoclonal antibody injection combined with CHOP (Hi CHOP) regimen in previously untreated patients with diffuse large B-cell&#32

    Excerpt:
    ...Previously untreated patients with a confirmed pathologic diagnosis of Diffuse large B cell-non-Hodgkin's lymphoma (DLBCL) and CD20 positive in immunohistochemical test. ...
    Trial ID:
    ChiCTR2100042104
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

    Excerpt:
    ...- CD20-positive disease...
    Trial ID:
    NCT00039195
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patients

    Excerpt:
    ...Patients with histological confirmed CD20 positive diffuse large B cell lymphoma (DLBCL);Patients that had been diagnosed according to the WHO classification;Performance status ≤ 2 on the ECOG/WHO scale, performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated;Patients eligible for rituximab treatment according to MabThera indications;Life expectance at least 6 months;Laboratory values within normal range unless abnormalities are related to lymphoma. ...
    Trial ID:
    2013-005506-56
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

    Excerpt:
    ...Histologically confirmed CD20 positive DLBCL 2....
    Trial ID:
    NCT02792491
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL

    Excerpt:
    ...- Histologically confirmed CD20-positive Diffuse Large B-cell Lymphoma (DLBCL), NOS...
    Trial ID:
    ASPIRE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

    Excerpt:
    ...- Pathologically confirmed diagnosis of CD20-positive diffuse large B-cell lymphoma...
    Trial ID:
    NCT02428751
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) being treated in haemato-oncology units within South East Wales

    Excerpt:
    ...Ideally fresh biopsy material should be available at diagnosisd) Bulky stage 1A-1V diseasee) CD20 positive diseasef) Previously untreated diseaseg) No prior diagnosis of indolent lymphoma, including histological transformationh) No clinical evidence of CNS lymphomai) No active malignancy, other than BCC or squamous cell carcinoma of the skin or carcinoma of the cervix in situ, for the past 10 yearsj) Life expectancy > 3 monthsk) Adequate contraceptive precautions for women of childbearing agel) No concurrent uncontrolled medical condition...
    Trial ID:
    2006-003333-33
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

    Excerpt:
    ...- Diagnosis of CD20-positive diffuse large B-cell lymphoma, including any of the following morphological variants:...
    Trial ID:
    NCT00851552
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

    Excerpt:
    ...- Tumors must be CD20 positive...
    Trial ID:
    NCT00049036
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, eligible for transplantation followed by randomised maintenance treatment with Rituximab

    Excerpt:
    ...Patients with CD20 positive diffuse large B-cell lymphoma.Disease must be histologically proven in case ofrelapse or partial responseAged 18-65 Eligible for transplanatationECOG performance ...
    Trial ID:
    2004-002103-32
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Prospective multicenter phase I-II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL).

    Excerpt:
    ...Histologic subtypes as follows: a. CD20 positive Diffuse large B-Cell lymphoma b. CD20 positive Follicular grade IIIb 2. ...
    Trial ID:
    2007-003560-21
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas

    Excerpt:
    ...- Patients must have CD20 positive tumors....
    Trial ID:
    IELSG33
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

    Excerpt:
    ...- Histologically confirmed cluster of differentiation antigen 20 (CD20) positive Diffuse Large B-Cell Lymphoma according to the World Health Organization/Revised European-American Classification of Lymphoid Neoplasms (WHO/REAL) classification - Age > or =18 years - Performance status < or = 2 on the Eastern Cooperative Oncology Group (ECOG) scale - Women of child-bearing potential must agree to use effective contraception for the entire treatment period and during the 12 months thereafter ...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Split-Dose R-CHOP for Older Adults With DLBCL

    Excerpt:
    ...- Newly diagnosed, untreated, biopsy proven CD20 positive DLBCL (including high grade B-cell lymphoma & T-cell/histiocytic rich large B-cell lymphoma)....
    Trial ID:
    NCT03943901
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

    Excerpt:
    ...- Previously untreated primary mediastinal diffuse large B-cell lymphoma, CD20 positive....
    Trial ID:
    IELSG37
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

    Excerpt:
    ...Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI)....
    Trial ID:
    NCT00006436
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

    Excerpt:
    ...- Pathologically confirmed CD20 positive DLBCL based on 2016 WHO classification who achieved CR after 4 cycles of RCHOP therapy (examined by PET-CT, Deauville score 1-2)...
    Trial ID:
    NCT05018520
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells....
    Trial ID:
    NCT03372837
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

    Excerpt:
    ...Histologically proven CD20 positive Diffuse Large B-cell Lymphoma according to WHO classification (local pathologist) 2....
    Trial ID:
    NCT02955823
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

    Excerpt:
    ...- Previously untreated CD-20 positive follicular NHL...
    Trial ID:
    NCT02240316
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

    Excerpt:
    ...- Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which...
    Trial ID:
    NCT01307267
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...Phase I and Phase II: Confirmed diagnosis of mantle cell lymphoma with CD20 positivity in tissue biopsy....
    Trial ID:
    NCT00294632
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

    Excerpt:
    ...- Patients with CD20-positive diffuse large B-cell lymphoma....
    Trial ID:
    NCT00137995
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma

    Excerpt:
    ...- Histologically confirmed CD20 positive primary breast DLBCL...
    Trial ID:
    NCT01448096
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

    Excerpt:
    ...Histologically confirmed CD20-positive DLBCL (The germinal center B-cell like (GCB) / non-GCB subtype was determined by immunohistochemistry in paraffin-embedded tissue using CD10, BCL6 and MUM1 protein markers based on Hans's algorithm); 2....
    Trial ID:
    NCT01670370
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

    Excerpt:
    ...- Cluster of Differentiation 20 (CD20) positive b lymphocytes....
    Trial ID:
    BRCAP-GELTAMO12
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

    Excerpt:
    ...- Biopsy confirmed, CD20 positive diffuse large B-cell lymphoma, primary mediastinal b-cell lymphoma, mantel cell lymphoma, transformed indolent lymphoma, high grade-B-cell lymphoma; AND bone marrow must show == 15% cellularity within 42 days of study registration...
    Trial ID:
    NCT01686165
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Lenalidomide and R-CHOP in B-cell Lymphoma

    Excerpt:
    ...- Patients with one of the following B-cell Lymphoma, CD 20 positive:...
    Trial ID:
    NCT00901615
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

    Excerpt:
    ...- Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have...
    Trial ID:
    NCT00299494
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Excerpt:
    ...- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy...
    Trial ID:
    NCT00867087
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...- Untreated, histological diagnosis of CD20-positive diffuse large B-cell lymphoma...
    Trial ID:
    NCT01334502
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

    Excerpt:
    ...Histologically confirmed CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) 2....
    Trial ID:
    NCT01054781
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma

    Excerpt:
    ...- CD20 positive Diffuse large B-Cell lymphoma...
    Trial ID:
    REAL07
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma

    Excerpt:
    ...Histologically confirmed CD20 positive DLBCL 2....
    Trial ID:
    NCT01181999
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

    Excerpt:
    ...- Patients with CD20-positive diffuse large B-cell lymphoma...
    Trial ID:
    LINFOTARGAM
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    R Retreatment in 1st Relapsed DLBCL

    Excerpt:
    ...Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction therapy) 4....
    Trial ID:
    NCT00980304
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

    Excerpt:
    ...- CD20-positive disease...
    Trial ID:
    NCT00689845
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A multicenter, prospective, simultaneous controlled and exploratory clinical study on the treatment of new dignosed Diff typinguse large B-cell Lymphoma with RCHOP regimen and X drugs under the guidance of Next Generation Sequencing

    Excerpt:
    ...1) Diffuse large B-cell lymphoma with positive CD20 was confirmed by histopathology. ...
    Trial ID:
    ChiCTR2300068820
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A preliminary clinical trial on the safety and efficacy of high-purity human NK cell (hpNK) injection combined with rituximab in the treatment of CD20-positive diffuse large B-cell lymphoma (CD20+ r/r DLBCL)

    Excerpt:
    ...Histologically confirmed CD20-positive (CD20+) relapsed or refractory diffuse large B-cell lymphoma (DLBCL); 3. ...
    Trial ID:
    ChiCTR2000040177
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution

    Excerpt:
    ...All risk groups with good general condition (ECOG 0-2) without majour accompanying diseases after patient's information and written patient's informed consent Patienten im Alter von 61 bis 80 Jahren mit neu diagnostiziertem CD20-positivem aggressivem Lymphom aller Risikogruppen in gutem Allgemeinzustand (ECOG 0-2) ohne wesentliche Begleiterkrankungen nach Aufklärung und schriftlicher Einverständniserklärung...
    Trial ID:
    2010-019587-36
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory diffuse large B cell lymphoma.

    Excerpt:
    ...Histologically proven CD 20 positive diffuse large B cell lymphoma, previously treated with a chemotherapy regimen with or without rituximab in patients who have relapsed or are refractory; with a minimum life expectancy of 3 months. ...
    Trial ID:
    ACTRN12605000236695
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Ofatumumab for the treatment of lymphomalease

    Excerpt:
    ...CD20 positive DLBCL or grade 3b follicular lymphoma (FL) at original diagnosis. ...
    Trial ID:
    2009-009256-20
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A phase III, open-label, prospective, two-armed, multicenter, randomized,group sequential study to evaluate the efficacy and safety of subsequenttreatment with the Zevalin (ibritumomab tiuxetan) study regimen versusobservation in patients with diffuse large B-cell lymphoma who are incomplete remission after first-line CHOP-rituximab (CHOP-R) therapy

    Excerpt:
    ...Central pathology review confirming the DLBCL diagnosis and CD20 positivity, and no evidence of DLBCL in bone marrow3. ...
    Trial ID:
    2005-001727-11
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma

    Excerpt:
    ...For first randomization: - Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL) based upon a representative histology specimen according to the WHO classification (see appendix A) - DLBCL must be CD20 positive - Ann Arbor stages II-IV (see appendix C) - Age 18-65 years and age-adjusted IPI 1-3 OR age 66-80 years and age-adjusted IPI 0-3 - WHO performance status 0 – 2 (see appendix E) - Written informed consent For second randomization: Patients achieving a CR (or FDG-PET negative PR/CRu) after 6 (elderly) or 8 (young patients) cycles of R-CHOP14 will be randomized to maintenance treatment with rituximab or no further treatment. ...
    Trial ID:
    2006-005174-42
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    PET-RIMCEB:Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patientsA phase III studyA randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas+A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas

    Excerpt:
    ...• Age 18-60 years• Newly diagnosed, CD20 positive, untreated diffuse large B-cell lymphoma or composite follicular/diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma (according to the WHO classification) • High intermediate or high risk according to age adjusted International Prognostic Index (aaIPI 2-3) • No significant organ dysfunction, no active uncontrolled disease• ECOG Performance Status 0-3 • Ejection fraction of at least 50% as determined by echocardiography or alternative suitable method • Signed informed consent...
    Trial ID:
    2009-016136-12
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2021
    Title:

    RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R-NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL AND PATHOLOGICAL FACTORS

    Published date:
    06/09/2021
    Excerpt:
    ...data of patients 80 years or older with untreated histologically-proven CD20-positive DLBCL...Our results confirm that, in patients 80 years or older with DLBCL, R-NPDL is very effective and safe combination.
    Secondary therapy:
    non-pegylated liposomal doxorubicin